CD19 and acute lymphoblastic leukemia: Fifty-five (55.7%) patients with ALL (5 Ph-positive ALL and 14 received allogeneic hematopoietic stem cell transplantation previously) received anti-CD19 CAR-T cell, and 25 patients with MM, including 11 (7.7%) type IgG, 5 (3.5%) IgA, 5 (3.5%) light chain, and 4 (2.8%) other types.